Statistical analysis
OVARIAN CANCER, SECONDARY
The study was conducted using Simon’s two-stage optimal design with assumptions concerning the estimated PFS rate in ovarian cancer. As the benchmark for the null hypothesis, we chose the GOG-213 study, which investigated chemotherapy plus bevacizumab followed by bevacizumab maintenance regardless of The proportion of patients achieving responses and 95% CIs was assessed using the Clopper–Pearson exact method. Survival analyses were pre-specified as secondary endpoints. The PFS and associated 95% CIs were calculated using the Kaplan–Meier method. A log-rank test was used to compare the PFS between the patient subsets. Statistical analyses were performed using SAS (version 9.4; SAS Institute, Cary, NC, USA).